title: Effect of cytochrome P450-dependent epoxyeicosanoids on Ristocetin-induced thrombocyte aggregation.
abstract: Epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 (CYP)-dependent epoxidation of arachidonic acid (AA) inhibit thrombocyte adhesion to the vascular wall. Upon dietary omega-3 fatty acid supplementation, EETs are partially replaced by eicosapentaenoic acid (EPA)-derived epoxyeicosatetraenoic acids (EEQs) and docosahexaenoic acid (DHA)-derived epoxydocosapentaenoic acids (EDPs). We hypothesized that the omega-3 epoxy-metabolites may exhibit superior anti-thrombogenic properties compared to their AA-derived counterparts. To test this hypothesis, we analyzed the effects of 11,12-EET, 17,18-EEQ and 19,20-EDP on Ristocetin-induced thrombocyte aggregation (RITA), a process that mimics thrombocyte adhesion to the vascular wall. The eicosanoids were added for 5, 30, or 60 minutes to thrombocyte-rich plasma freshly prepared immediately after blood collection from stringently selected apparently healthy subjects. Thrombocyte aggregation was then induced by Ristocetin (0.75 mg/mL) and assessed by turbidimetric measurements. After 60 minutes of preincubation, all three epoxy-metabolites significantly decreased the rate of RITA. 17,18-EEQ and 19,20-EDP were effective already at 1 μM, whereas 5-fold higher concentrations were required with 11,12-EET. Addition of AUDA, an inhibitor of the soluble epoxide hydrolase, potentiated the effect of 17,18-EEQ resulting in a significant further decrease of the velocity as well as amplitude of the aggregation process. In contrast to their profound effects on RITA, none of the epoxy-metabolites was effective in reducing collagen- or ADP-induced thrombocyte aggregation. These results indicate a highly specific role of CYP-eicosanoids in preventing thromboembolic events and suggest that the formation of 17,18-EEQ and 19,20-EDP may contribute to the anti-thrombotic effects of omega-3 fatty acids.
authors.affiliation: Center for Biomaterial Development and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Institute of Polymer Research, Helmholtz-Zentrum Geesthacht, Teltow, Germany. friedrich.jung@hzg.de
authors.forename: F
authors.initials: F
authors.lastname: Jung
authors.forename: C
authors.initials: C
authors.lastname: Schulz
authors.forename: F
authors.initials: F
authors.lastname: Blaschke
authors.forename: D N
authors.initials: DN
authors.lastname: Muller
authors.forename: C
authors.initials: C
authors.lastname: Mrowietz
authors.forename: R P
authors.initials: RP
authors.lastname: Franke
authors.forename: A
authors.initials: A
authors.lastname: Lendlein
authors.forename: W-H
authors.initials: WH
authors.lastname: Schunck
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001792:Blood Platelets / Q000166:cytology* / Q000187:drug effects*; D002449:Cell Aggregation / Q000187:drug effects; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D015777:Eicosanoids / Q000378:metabolism* / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D012310:Ristocetin / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D015777:Eicosanoids; D012310:Ristocetin; D003577:Cytochrome P-450 Enzyme System